{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:51:31Z","timestamp":1792144291780,"version":"4.4.0"},"reference-count":134,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["T-B-070"],"award-info":[{"award-number":["T-B-070"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272951"],"award-info":[{"award-number":["82272951"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272953"],"award-info":[{"award-number":["82272953"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005149","name":"Cancer Hospital Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005149","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508500"],"award-info":[{"award-number":["2023YFC2508500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.medj.2025.100986","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:14:06Z","timestamp":1770308046000},"page":"100986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Advances and perspectives in CEA-targeted therapies: From classic biomarker toward actionable therapeutic target"],"prefix":"10.1016","volume":"7","author":[{"given":"Liangjie","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3945-2536","authenticated-orcid":false,"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100986_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1084\/jem.122.3.467","article-title":"Specific carcinoembryonic antigens of the human digestive system","volume":"122","author":"Gold","year":"1965","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.medj.2025.100986_bib2","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1073\/pnas.84.9.2960","article-title":"Isolation and characterization of cDNA clones encoding the human carcinoembryonic antigen reveal a highly conserved repeating structure","volume":"84","author":"Zimmermann","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2025.100986_bib3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1083\/jcb.122.4.951","article-title":"Homophilic adhesion between Ig superfamily carcinoembryonic antigen molecules involves double reciprocal bonds","volume":"122","author":"Zhou","year":"1993","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.medj.2025.100986_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000217555","article-title":"Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult","volume":"9","author":"Nap","year":"1988","journal-title":"Tumour Biol."},{"key":"10.1016\/j.medj.2025.100986_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/scbi.1998.0119","article-title":"The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues","volume":"9","author":"Hammarstr\u00f6m","year":"1999","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.medj.2025.100986_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16234052","article-title":"Carcinoembryonic Antigen Expression in Human Tumors: A Tissue Microarray Study on 13,725 Tumors","volume":"16","author":"Jansen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medj.2025.100986_bib7","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/bjc.2012.422","article-title":"Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma","volume":"107","author":"Kobayashi","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/01.sla.0000154455.86404.e9","article-title":"CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions","volume":"241","author":"Duxbury","year":"2005","journal-title":"Ann. Surg."},{"key":"10.1016\/j.medj.2025.100986_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12893-022-01667-z","article-title":"Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer","volume":"22","author":"Shibata","year":"2022","journal-title":"BMC Surg."},{"key":"10.1016\/j.medj.2025.100986_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/gutjnl-2018-316027","article-title":"European evidence-based guidelines on pancreatic cystic neoplasms","volume":"67","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.medj.2025.100986_bib11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0092-8674(89)90970-7","article-title":"Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule","volume":"57","author":"Benchimol","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.medj.2025.100986_bib12","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1073\/pnas.1509511112","article-title":"Diverse oligomeric states of CEACAM IgV domains","volume":"112","author":"Bonsor","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2025.100986_bib13","first-page":"3419","article-title":"Human carcinoembryonic antigen functions as a general inhibitor of anoikis","volume":"60","author":"Ordo\u00f1ez","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/jcp.20887","article-title":"GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction","volume":"210","author":"Ordonez","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.medj.2025.100986_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101179","article-title":"CEA-induced PI3K\/AKT pathway activation through the binding of CEA to KRT1 contributes to oxaliplatin resistance in gastric cancer","volume":"78","author":"Chen","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.medj.2025.100986_bib16","doi-asserted-by":"crossref","first-page":"8159","DOI":"10.1158\/0008-5472.CAN-10-1073","article-title":"Carcinoembryonic antigen interacts with TGF-\u03b2 receptor and inhibits TGF-\u03b2 signaling in colorectal cancers","volume":"70","author":"Li","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235840","article-title":"Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity","volume":"14","author":"Huang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medj.2025.100986_bib18","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1158\/0008-5472.CAN-04-4140","article-title":"Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin","volume":"65","author":"van Gisbergen","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib19","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.bjc.6604289","article-title":"Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen","volume":"98","author":"Conaghan","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib20","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1158\/0008-5472.CAN-13-0123","article-title":"Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis","volume":"73","author":"Bramswig","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib21","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/ijc.31586","article-title":"Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells","volume":"143","author":"Abdul-Wahid","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib22","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jtho.2024.09.050","article-title":"OA08.05 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial","volume":"19","author":"Besse","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/14712598.7.4.543","article-title":"PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma","volume":"7","author":"Madan","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.medj.2025.100986_bib24","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2025.100986_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13046-023-02649-6","article-title":"First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors","volume":"42","author":"Cole","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib26","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1200\/JCO.2025.43.16_suppl.4018","article-title":"Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study","volume":"43","author":"Lentz","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib27","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1158\/1538-7445.AM2025-4364","article-title":"Abstract 4364: Preclinical pharmacokinetics and pharmacodynamics of MK-4464, a novel NK cell engager targeting CEACAM5","volume":"85","author":"Nayak","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib28","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1200\/JCO.2025.43.16_suppl.8517","article-title":"Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial","volume":"43","author":"Wei","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.medj.2025.100986_bib31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1078-0432.CCR-20-3396","article-title":"Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer","volume":"27","author":"DeLucia","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib32","first-page":"3221","article-title":"Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen","volume":"7","author":"Beauchemin","year":"1987","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.medj.2025.100986_bib33","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.4049\/jimmunol.174.11.6692","article-title":"Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1","volume":"174","author":"Stern","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2025.100986_bib34","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/gut.18.10.786","article-title":"Carcinoembryonic antigen (CEA) in the normal human small intestine: a light and electron microscopic study","volume":"18","author":"Isaacson","year":"1977","journal-title":"Gut"},{"key":"10.1016\/j.medj.2025.100986_bib35","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/1097-0142(19820515)49:10<2077::AID-CNCR2820491020>3.0.CO;2-X","article-title":"Ultrastructural localization of carcinoembryonic antigen in normal intestine and colon cancer: abnormal distribution of CEA on the surfaces of colon cancer cells","volume":"49","author":"Ahnen","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039908","article-title":"Extracellular IgC2 constant domains of CEACAMs mediate PI3K sensitivity during uptake of pathogens","volume":"7","author":"Voges","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2025.100986_bib37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1462-5822.2006.00789.x","article-title":"Mutational analysis of human CEACAM1: the potential of receptor polymorphism in increasing host susceptibility to bacterial infection","volume":"9","author":"Villullas","year":"2007","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.medj.2025.100986_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1741-7007-8-12","article-title":"Coevolution of activating and inhibitory receptors within mammalian carcinoembryonic antigen families","volume":"8","author":"Kammerer","year":"2010","journal-title":"BMC Biol."},{"key":"10.1016\/j.medj.2025.100986_bib39","first-page":"671","article-title":"Carcinoembryonic antigen in normal and diseased liver tissue","volume":"92","author":"Gerber","year":"1978","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.medj.2025.100986_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/00365527909179883","article-title":"Carcinoembryonic antigen (CEA) in patients with alcoholic liver diseases","volume":"14","author":"Bell","year":"1979","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.medj.2025.100986_bib41","first-page":"3817","article-title":"Specificity of anti-carcinoembryonic antigen monoclonal antibodies and their effects on CEA-mediated adhesion","volume":"53","author":"Zhou","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.neo.7900201","article-title":"Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation","volume":"4","author":"Ilantzis","year":"2002","journal-title":"Neoplasia"},{"key":"10.1016\/j.medj.2025.100986_bib43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1083\/jcb.123.2.467","article-title":"Human carcinoembryonic antigen, an intercellular adhesion molecule, blocks fusion and differentiation of rat myoblasts","volume":"123","author":"Eidelman","year":"1993","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.medj.2025.100986_bib44","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1083\/jcb.137.4.939","article-title":"Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation","volume":"137","author":"Screaton","year":"1997","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.medj.2025.100986_bib45","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s10495-007-0138-9","article-title":"An altered fibronectin matrix induces anoikis of human squamous cell carcinoma cells by suppressing integrin alpha v levels and phosphorylation of FAK and ERK","volume":"12","author":"Kamarajan","year":"2007","journal-title":"Apoptosis"},{"key":"10.1016\/j.medj.2025.100986_bib46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/jcp.20989","article-title":"A co-clustering model involving alpha5beta1 integrin for the biological effects of GPI-anchored human carcinoembryonic antigen (CEA)","volume":"211","author":"Camacho-Leal","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.medj.2025.100986_bib47","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-06-4315","article-title":"Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with TRAIL-R2 (DR5) signaling","volume":"67","author":"Samara","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib48","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1021\/acs.jproteome.0c00875","article-title":"Site-Specific N-Linked Glycosylation Analysis of Human Carcinoembryonic Antigen by Sheathless Capillary Electrophoresis-Tandem Mass Spectrometry","volume":"20","author":"Pont","year":"2021","journal-title":"J. Proteome Res."},{"issue":"3","key":"10.1016\/j.medj.2025.100986_bib49","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1021\/acs.jproteome.0c00875","article-title":"Site-specific N-linked glycosylation analysis of human carcinoembryonic antigen by sheathless capillary electrophoresis\u2013tandem mass spectrometry","volume":"20","author":"Pont","year":"2021","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.medj.2025.100986_bib50","first-page":"5647","article-title":"Expression of carcinoembryonic antigen and its predicted immunoglobulin-like domains in HeLa cells for epitope analysis","volume":"52","author":"Hefta","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib51","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3389\/fimmu.2019.02120","article-title":"Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis","volume":"10","author":"L\u00e4ubli","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100986_bib52","unstructured":"Cote, R., Fradet, Y., and Daly, M. (1985). Antigenic masking: modification of a tumor cell surface antigen (OM5) by progressive sialylation."},{"key":"10.1016\/j.medj.2025.100986_bib53","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.4049\/jimmunol.168.5.2118","article-title":"The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells","volume":"168","author":"Engering","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2025.100986_bib54","doi-asserted-by":"crossref","first-page":"22403","DOI":"10.1074\/jbc.M110.215301","article-title":"Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas","volume":"286","author":"Nonaka","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.medj.2025.100986_bib55","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/eji.201242676","article-title":"CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling","volume":"43","author":"Hosomi","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.medj.2025.100986_bib56","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2002.05.033","article-title":"CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease","volume":"20","author":"Thies","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib57","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/onc.2012.112","article-title":"Host-related carcinoembryonic antigen cell adhesion molecule 1 promotes metastasis of colorectal cancer","volume":"32","author":"Arabzadeh","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.medj.2025.100986_bib58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","article-title":"Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer","volume":"22","author":"Chen","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib59","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1476-5381.2009.00291.x","article-title":"Arginase: an emerging key player in the mammalian immune system","volume":"158","author":"Munder","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.medj.2025.100986_bib60","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/imr.12160","article-title":"tTregs, pTregs, and iTregs: similarities and differences","volume":"259","author":"Shevach","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.medj.2025.100986_bib61","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev.med.49.1.407","article-title":"Angiogenesis and tumor metastasis","volume":"49","author":"Zetter","year":"1998","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.medj.2025.100986_bib62","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/abbs\/gmx147","article-title":"Correlation between circulating endothelial progenitor cells and serum carcinoembryonic antigen level in colorectal cancer","volume":"50","author":"Li","year":"2018","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.medj.2025.100986_bib63","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00384-014-2116-3","article-title":"Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome","volume":"30","author":"Ramcharan","year":"2015","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.medj.2025.100986_bib64","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10585-011-9419-3","article-title":"Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver","volume":"28","author":"Thomas","year":"2011","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.medj.2025.100986_bib65","first-page":"4805","article-title":"Carcinoembryonic antigen induces cytokine expression in Kuppfer cells: implications for hepatic metastasis from colorectal cancer","volume":"56","author":"Gangopadhyay","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib66","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.medj.2025.100986_bib67","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1515\/CCLM.2009.212","article-title":"Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers","volume":"47","author":"Emara","year":"2009","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.medj.2025.100986_bib68","first-page":"689","article-title":"The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis","volume":"71","author":"Dranka-Bojarowska","year":"2020","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.medj.2025.100986_bib69","article-title":"CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration","volume":"48","author":"Zhang","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.medj.2025.100986_bib70","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1093\/ajcp\/aqad150.080","article-title":"Carcinoembryonic antigen (CEA) expression in human tumors: A tissue microarray study on 15,413 tumors","volume":"160","author":"Jansen","year":"2023","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.medj.2025.100986_bib71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejso.2011.10.013","article-title":"Prognostic models for outcome following liver resection for colorectal cancer metastases: A systematic review","volume":"38","author":"Spelt","year":"2012","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib72","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.4240\/wjgs.v15.i12.2890","article-title":"Prognostic role of serum carcinoembryonic antigen in patients receiving liver resection for colorectal cancer liver metastasis: A meta-analysis","volume":"15","author":"Tang","year":"2023","journal-title":"World J. Gastrointest. Surg."},{"key":"10.1016\/j.medj.2025.100986_bib73","first-page":"601","article-title":"Application value of serum CEA, CA19-9 and CA242 in opportunistic screening for colorectal cancer in Chinese population: a meta-analysis","volume":"18","author":"Yu Li","year":"2024","journal-title":"Chinese Journal of Health Management"},{"key":"10.1016\/j.medj.2025.100986_bib74","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/bjc.2012.605","article-title":"Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting","volume":"108","author":"Tiernan","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib75","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamaoncol.2017.4420","article-title":"Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome","volume":"4","author":"Konishi","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.1974.03230260023017","article-title":"Serial carcinoembryonic antigen assays. Use in detection of cancer recurrence","volume":"228","author":"Sorokin","year":"1974","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2025.100986_bib77","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2005.04.0063","article-title":"Colorectal Cancer Surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline","volume":"23","author":"Desch","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib78","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/01.sla.0000154455.86404.e9","article-title":"CEACAM6 Is a Novel Biomarker in Pancreatic Adenocarcinoma and PanIN Lesions","volume":"241","author":"Duxbury","year":"2005","journal-title":"Ann. Surg."},{"key":"10.1016\/j.medj.2025.100986_bib79","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-04-0424","article-title":"A Novel Role for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 as a Determinant of Gemcitabine Chemoresistance in Pancreatic Adenocarcinoma Cells","volume":"64","author":"Duxbury","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib80","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/1354750X.2020.1725786","article-title":"Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis","volume":"25","author":"van Manen","year":"2020","journal-title":"Biomarkers"},{"key":"10.1016\/j.medj.2025.100986_bib81","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/gutjnl-2018-316027","article-title":"European evidence-based guidelines on pancreatic cystic neoplasms","volume":"67","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.medj.2025.100986_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.medj.2025.100986_bib83","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3892\/ol.2022.13528","article-title":"Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma","volume":"24","author":"Sun","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.medj.2025.100986_bib84","first-page":"335","article-title":"The Significance of Serum Carcinoembryonic Antigen in Lung Adenocarcinoma","volume":"48","author":"Kim","year":"2015","journal-title":"J Chest Surg"},{"key":"10.1016\/j.medj.2025.100986_bib85","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/bjc.1993.300","article-title":"Expression of carcinoembryonic antigen (CEA) and nonspecific crossreacting antigen (NCA) in gastrointestinal cancer; the correlation with degree of differentiation","volume":"68","author":"Kodera","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib86","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3892\/mco.2015.712","article-title":"Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer","volume":"4","author":"Yu","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib87","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1040-8428(85)80008-1","article-title":"Cea-related antigens: Molecular biology and clinical significance","volume":"2","author":"Shively","year":"1985","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.medj.2025.100986_bib88","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/bjs.8980","article-title":"Expression of cell adhesion molecules and prognosis in breast cancer","volume":"100","author":"Saadatmand","year":"2013","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.medj.2025.100986_bib89","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cca.2015.06.022","article-title":"Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients","volume":"448","author":"Stieber","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.medj.2025.100986_bib90","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13277-010-0025-9","article-title":"Evaluation of tumor markers (HER-2\/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value","volume":"31","author":"Molina","year":"2010","journal-title":"Tumor Biol."},{"key":"10.1016\/j.medj.2025.100986_bib91","first-page":"68","article-title":"Carcinoembryonic antigen: an invaluable marker for advanced breast cancer","volume":"42","author":"Pathak","year":"1996","journal-title":"J. Postgrad. Med."},{"key":"10.1016\/j.medj.2025.100986_bib92","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5529106","article-title":"Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer","volume":"2021","author":"Zhao","year":"2021","journal-title":"Dis. Markers"},{"key":"10.1016\/j.medj.2025.100986_bib93","doi-asserted-by":"crossref","first-page":"1418657","DOI":"10.3389\/fendo.2024.1418657","article-title":"Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.medj.2025.100986_bib94","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1186\/s12967-023-04801-4","article-title":"Integrated plasma metabolomics and lipidomics profiling highlights distinctive signature of hepatocellular carcinoma in HCV patients","volume":"21","author":"Caponigro","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.medj.2025.100986_bib95","doi-asserted-by":"crossref","DOI":"10.1177\/15593258221097589","article-title":"Screening of Prognostic Biomarkers for Stereotactic Body Radiation Therapy in Primary Liver Cancer","volume":"20","author":"Liang","year":"2022","journal-title":"Dose Response"},{"key":"10.1016\/j.medj.2025.100986_bib96","article-title":"Clinical value of blood routine and tumor markers in differentiating hepatocellular carcinoma from intrahepatic cholangiocarcinoma","volume":"104","author":"Shi","year":"2025","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.medj.2025.100986_bib97","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s13402-025-01092-3","article-title":"Apo10 and TKTL1 in blood macrophages as non-invasive biomarkers for early detection of cervical cancer","volume":"48","author":"Wang","year":"2025","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib98","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S1556-0864(23)00267-8","article-title":"13MO Safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab \u00b1 chemotherapy in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05 phase II study)","volume":"18","author":"Isambert","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib99","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1556-0864(25)00224-2","article-title":"29P: Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial","volume":"20","author":"Lena","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib100","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase I\/II Trial of Labetuzumab Govitecan (Anti-CEACAM5\/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.642","article-title":"573P M9140, an anti-CEACAM5 antibody drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): Updated results from a phase I trial","volume":"35","author":"Boni","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib113","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.2024.42.16_suppl.3000","article-title":"First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC)","volume":"42","author":"Kopetz","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib103","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1158\/1538-7445.AM2024-2118","article-title":"Abstract 2118: SGN-CEACAM5C\/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has potent anti-tumor activity in CRC, PDAC, GC and lung cancer tumor models","volume":"84","author":"Baudat","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib114","first-page":"TPS2670","article-title":"A phase 1\/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors","volume":"43","author":"Dumbrava","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41401-023-01200-9","article-title":"A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity","volume":"45","author":"Zhu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.medj.2025.100986_bib116","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1538-7445.AM2025-342","article-title":"Abstract 342: First-in-class click chemistry-based pre-targeting of CEACAM5 tumor antigen selectively activates an MMAE payload at tumors","volume":"85","author":"Coricor","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib102","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1538-7445.AM2025-5461","article-title":"Abstract 5461: BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models","volume":"85","author":"He","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib104","first-page":"A724","article-title":"634 EVEREST-1: A seamless phase 1\/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)","volume":"11","author":"Punekar","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.2025.43.4_suppl.123","article-title":"First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors","volume":"43","author":"Desai","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1378813","article-title":"Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 \u03ba\u03bb bispecific antibody","volume":"15","author":"Seckinger","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100986_bib107","article-title":"853 Novel CEAxCD47 (NILK-2401) and CEAxCD3 (NILK-2301) kl bispecific antibodies for multimodal immunotherapy of CEA-expressing solid cancer","volume":"10","author":"Anja","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib108","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13045-023-01516-3","article-title":"Development and characterization of NILK-2301, a novel CEACAM5xCD3 \u03ba\u03bb bispecific antibody for immunotherapy of CEACAM5-expressing cancers","volume":"16","author":"Seckinger","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib109","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamaoncol.2015.2736","article-title":"Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial","volume":"1","author":"Heery","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib110","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00262-022-03274-6","article-title":"Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma","volume":"72","author":"Sonpavde","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.medj.2025.100986_bib111","first-page":"A673","article-title":"592 Updated recurrence free survival for neoadjuvant bintrafusp alfa (BA) for HPV unrelated HNSCC and results from BA plus a multitargeted recombinant adenovirus 5 vaccine for HPV unrelated HNSCC","volume":"11","author":"Redman","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib112","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41467-023-43076-7","article-title":"Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial","volume":"15","author":"Galanis","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2025.100986_bib117","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1200\/JCO.2024.42.16_suppl.3514","article-title":"Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2025.03.386","article-title":"Development of CT109-CAR-T, a novel CAR-T therapy for solid tumors manufactured at Point of Care (POC)","volume":"27","author":"Nahum","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.medj.2025.100986_bib119","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1016\/j.ymthe.2024.06.023","article-title":"Preclinical efficacy of a HER2 synNotch\/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification","volume":"32","author":"Cortese","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.medj.2025.100986_bib120","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/j.annonc.2024.08.159","article-title":"151P Enhanced pharmacodynamic effects upon combination of cibisatamab and FAP-4-1BBL in 3L+ mMSS CRC patients","volume":"35","author":"Melero","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib121","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/SLA.0b013e318292919e","article-title":"A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer","volume":"258","author":"Morse","year":"2013","journal-title":"Ann. Surg."},{"key":"10.1016\/j.medj.2025.100986_bib122","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1158\/1078-0432.CCR-19-0183","article-title":"A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules","volume":"25","author":"Gatti-Mays","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100986_bib123","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.2023.41.4_suppl.103","article-title":"HCRN GI16-288: A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer\u2014Preliminary efficacy and correlative results","volume":"41","author":"Spencer","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib124","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ijc.34267","article-title":"Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer","volume":"152","author":"Rajan","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib125","series-title":"Molecular Imaging and Contrast Agent Database (MICAD)","article-title":"(99m)Tc-Arcitumomab","author":"Cheng","year":"2004"},{"key":"10.1016\/j.medj.2025.100986_bib126","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41467-022-29630-9","article-title":"Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin","volume":"13","author":"de Gooyer","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2025.100986_bib127","doi-asserted-by":"crossref","first-page":"7616","DOI":"10.1038\/s41598-023-34855-9","article-title":"Clinical implication of tissue carcinoembryonic antigen expression in association with serum carcinoembryonic antigen in colorectal cancer","volume":"13","author":"Aldilaijan","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2025.100986_bib128","first-page":"365","article-title":"False elevations of carcinoembryonic antigen levels are common in patients under surveillance for colorectal cancer recurrence","volume":"64","author":"Barton","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.medj.2025.100986_bib129","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1002\/pmic.201600117","article-title":"Lectin inhibits antigen-antibody reaction in a glycoform-specific manner: Application for detecting \u03b12,6sialylated-carcinoembryonic antigen","volume":"16","author":"Ito","year":"2016","journal-title":"Proteomics"},{"key":"10.1016\/j.medj.2025.100986_bib130","article-title":"Control of lipid metabolism by the dynamic and nutrient-dependent post-translational modification O-GlcNAcylation","volume":"3","author":"Schulz","year":"2023","journal-title":"Natural Sciences"},{"key":"10.1016\/j.medj.2025.100986_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107356","article-title":"The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape","volume":"184","author":"Lefebvre","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.medj.2025.100986_bib132","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s12094-023-03339-7","article-title":"Correlation between carcinoembryonic antigen (CEA) expression and EGFR mutations in non-small-cell lung cancer: a meta-analysis","volume":"26","author":"Gan","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.medj.2025.100986_bib133","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1158\/1535-7163.MCT-23-0437","article-title":"Improving Intracellular Delivery of an Antibody\u2013Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo","volume":"23","author":"Nessler","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.medj.2025.100986_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13020299","article-title":"Anti-Drug Antibody Response to Therapeutic Antibodies and Potential Mitigation Strategies","volume":"13","author":"Howard","year":"2025","journal-title":"Biomedicines"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025004131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025004131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:36:22Z","timestamp":1773419782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025004131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666634025004131"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100986","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and perspectives in CEA-targeted therapies: From classic biomarker toward actionable therapeutic target","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100986","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100986"}}